Joint Formulary & PAD

Dydrogesterone - Menopausal disorders

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green (see narrative)
Formulations :
  • Tablets
Associated Icons :
Restrictions / Comments :
Important

(2nd line) as a treatment option in a HRT regime for women that do not tolerate the side effects of micronised progesterone.

PAD Profile

ChemicalSubstance :
Dydrogesterone
Indication :
Menopausal disorders
Group Name :
Keywords :
Menopause, menopausal symptoms, HRT, hormone replacement therapy, progesterone analogue, progestogen, adjunctive progestogen, endometrial protection
Brand Names Include :
Nalvee
Important Information :
Latest Additions Date From :
04 Feb 2026
Latest Additions Date To :
04 Mar 2026
Guidelines :
Supporting Documents :
3

Committee Recommendations (1)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed to add dydrogesterone tablets as an option for use in a Hormone Replacement Therapy (HRT) regime.

Dydrogesterone tablets for this indication will be given a GREEN (2nd line) traffic light status as a treatment option in HRT regime, for women that do not tolerate the side effects of micronised progesterone.